Chelation Therapy for Off-Label Uses
Policy governs coverage of chelation therapy for off-label indications (Alzheimer disease, atherosclerosis/cardiovascular disease, autism spectrum disorder, diabetes, multiple sclerosis, arthritis) and notes FDA-approved indications and guidance; defines these off-label uses as experimental/investigational and not covered. Applies to professional and institutional settings for BCBSKS members.
Policy states off-label applications (Alzheimer disease, atherosclerosis, autism, diabetes, multiple sclerosis, arthritis) are experimental/investigational.
Policy title changed to 'Chelation Therapy for Off-Label Uses' and policy language updated to restate FDA-approved indications in Policy Guidelines and identify off-label uses as experimental/investigational.
Policy guideline updated to change phrasing for iron overload indication to 'or' (transfusional hemosiderosis or NTDT).
Coding section updated over time (CPT correction: replaced 96375 with 96374) and removal of ICD diagnosis box; appendix changes and removal.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.